1.
Myers SA, Wright J, Peckner R, Kalish BT, Zhang F, Carr SA. Discovery of proteins associated with a predefined genomic locus via dCas9-APEX-mediated proximity labeling. Nat Methods. 2018;15(6):437-439. doi:10.1038/s41592-018-0007-1.
1.
Scott DA, Zhang F. Implications of human genetic variation in CRISPR-based therapeutic genome editing. Nat Med. 2017;23(9):1095-1101. doi:10.1038/nm.4377.
1.
Yamano T, Zetsche B, Ishitani R, Zhang F, Nishimasu H, Nureki O. Structural Basis for the Canonical and Non-canonical PAM Recognition by CRISPR-Cpf1. Mol Cell. 2017;67(4):633-645.e3. doi:10.1016/j.molcel.2017.06.035.
1.
Myhrvold C, Freije CA, Gootenberg JS, et al. Field-deployable viral diagnostics using CRISPR-Cas13. Science. 2018;360(6387):444-448. doi:10.1126/science.aas8836.
1.
Gootenberg JS, Abudayyeh OO, Kellner MJ, Joung J, Collins JJ, Zhang F. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science. 2018;360(6387):439-444. doi:10.1126/science.aaq0179.
1.
Maji B, Gangopadhyay SA, Lee M, et al. A High-Throughput Platform to Identify Small-Molecule Inhibitors of CRISPR-Cas9. Cell. 2019;177(4):1067-1079.e19. doi:10.1016/j.cell.2019.04.009.
1.
Cox DBT, Gootenberg JS, Abudayyeh OO, et al. RNA editing with CRISPR-Cas13. Science. 2017;358(6366):1019-1027. doi:10.1126/science.aaq0180.
1.
Pyzocha NK, Chen S. Diverse Class 2 CRISPR-Cas Effector Proteins for Genome Engineering Applications. ACS Chem Biol. 2018;13(2):347-356. doi:10.1021/acschembio.7b00800.
1.
Pan D, Kobayashi A, Jiang P, et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science. 2018;359(6377):770-775. doi:10.1126/science.aao1710.
1.
Wang M, Zuris JA, Meng F, et al. Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles. Proc Natl Acad Sci U S A. 2016;113(11):2868-73. doi:10.1073/pnas.1520244113.